Please login to the form below

Not currently logged in
Email:
Password:

Juniper Pharmaceuticals adds to board of directors

Mary Ann Gray joins as audit committee chair

Juniper Mary Ann GrayBoston-based Juniper Pharmaceuticals has elected Mary Ann Gray to its board of directors and appointed her as its audit committee chair.

Dr Gray has over 20 years of biotechnology and biopharmaceutical experience and is the owner and president of Gray Strategic Advisors as well as serving on the boards of Acadia Pharmaceuticals, Senomyx Inc. and TetraLogic Pharmaceuticals.

Prior to its acquisition by Shire earlier this year, Dr Gray was lead director at Dyax Corporation and has also held senior roles at the Federated Kaufmann Fund, GTC Biotherapeutics and Schering-Plough.

Jim Geraghty, Juniper's chairman, said: “Mary Ann is a highly qualified corporate director and experienced audit committee chair, and we are very pleased to have her join Juniper's board.

“Her unique blend of Wall Street, financial, and scientific experience will be a tremendous asset as Juniper continues to advance its clinical programs to drive long-term shareholder value.”

Gray succeeds Donald Hunter, who tendered his resignation from the board last year.

Geraghty added: “We deeply appreciate Don Hunter's contributions during his tenure on Juniper's board, and his willingness to provide continuity in his role as audit committee chair during our extensive search for the right person to succeed him.” 

6th April 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....

Infographics